In contrast, a case report indicated VGCV treatment was successfully completed by administering granulocyte-colony stimulating factor (G-CSF) to account for neutropenia [17], implying that neutropenia can be controlled by G-CSF. This evidence concerns the gene CSF3 and neutropenia.